Montserrat Sala

Universitat Autònoma de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Ferrán Segura

Corporació Sanitària Parc Taulí

Manuel Cervantes

Centro Español de Metrología

Bernat Font

Delft University of Technology

Ignasi Anguera

Bellvitge University Hospital

Manel Cervantes

Instituto Nacional de Perinatología

ÁU

Á Urbano-Márquez

Universitat de Barcelona

Dolors Mariscal

Corporació Sanitària Parc Taulí

María José Amengual

Hospital Universitario Son Espases

F. Segura

Hospital Privado

Bruno Frea

Azienda Ospedaliero Universitaria San Giovanni Battista

Cooperative Institutions

Instituto de Salud Carlos III

135

Centro de Investigación Biomédica en Red

113

Hospital Universitario Ramón y Cajal

Universitat Autònoma de Barcelona

Universitat de Barcelona

Corporació Sanitària Parc Taulí

Instituto Ramón y Cajal de Investigación Sanitaria

Universidad de Alcalá

Hospital General Universitario Gregorio Marañón

Hospital Clínic de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Neoplasia of plasma cells with atypical presentation and infection by the human immunodeficiency virus. A presentation of two cases

American Journal of Hematology (2000)

Susana Herranz Montserrat Sala Manel Cervantes Merc� Sasal A. Soler

Neoplasia of plasma cells acquires special clinical characteristics in patients infected by human immunodeficiency virus (HIV). These patients are much younger at the time of diagnosis, and when they are compared with the general population they show an atypical clinical evolution, with a greater frequency of solitary plasmacytomas, less evidence of a monoclonal plasmatic component, or greater aggressiveness of the neoplastic process. This paper provides the most significant data on two patients infected by HIV and diagnosed for plasma cell neoplasia. Recent pathogenetic hypotheses for plasma cell neoplasias that include immune alterations, chronic viral infections, and hyperexpression of cytokines exist in patients infected by HIV, and this could suggest that this type of neoplasia is another malignant haematological process associated with AIDS. Am. J. Hematol. 65:239–242, 2000. © 2000 Wiley-Liss, Inc.

10.1002/1096-8652(200011)65:3<239::aid-ajh11>3.0.co;2-6

Cite

Citations (13)

Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis.

PubMed (2000)

M. Larrosa Jordi Gratacós Montserrat Sala

Polymyalgia rheumatica

Erythrocyte sedimentation rate

Sedimentation

Source

Cite

Citations (7)

Thyroid carcinoma presenting as Pancoast's syndrome

Thorax (1991)

Alberto Rábano Montserrat Sala Pilar García Hernández Jefferson Luis de Barros

Abstract An unusual clinical presentation of papillary carcinoma of the thyroid is presented, which adds to the infrequent causes of the thoracic inlet syndrome.

Presentation (obstetrics)

10.1136/thx.46.4.270

Cite

Citations (15)

Epidemiological and clinical features, response to HAART, and survival in HIV-infected patients diagnosed at the age of 50 or more

BMC Infectious Diseases (2006)

María Mercedes Nogueras Gemma Navarro Esperança Antón Montserrat Sala Manel Cervantes

Over the last years, the mean age of subjects with HIV infection and AIDS is increasing. Moreover, some epidemiological and clinical differences between younger and older HIV-infected individuals have been observed. However, since introduction of HAART therapy, there are controversial results regarding their response to HAART. The aim of the present study is to evaluate epidemiological and clinical features, response to HAART, and survival in elderly HIV-infected patients with regard to younger HIV-infected patients. A prospective cohort study (1998–2003) was performed on patients from Sabadell Hospital, in Northeast of Spain. The cohort includes newly attended HIV-infected patients since January 1, 1998. For the purpose of this analysis, data was censured at December 31, 2003. Taking into account age at time of diagnosis, it was considered 36 HIV-positive people aged 50 years or more (Group 1, G1) and 419 HIV-positive people aged 13–40 years (Group 2, G2). Epidemiological, clinical, biological and therapy data are recorded. Statistical analysis was performed using Chi-squared test and Fisher exact test, Mann-Whitney U test, Kaplan-Meier, Log Rank test, and Two-Way ANOVA from random factors. G1 showed higher proportion of men than G2. The most common risk factors in G1 were heterosexual transmission (P = 0.01) and having sex with men or women (P < 0.001). G1 and G2 show parallel profiles through the time regarding immunological response (P = 0.989) and virological response (P = 0.074). However, older people showed lower CD4 cell counts at first clinic visit (P < 0.001) and, eventually, they did not achieve the same counts as G2. G1 presented faster progression to AIDS (P < 0.001) and shorter survival (P < 0.001). Older patients have different epidemiological features. Their immunological and virological responses are good. However, older patients do not achieve the same CD4 cell counts likely due to they have lower counts at first clinic visit. Thus, it is essential physicians know older HIV-infected patients features to consider the possibility of HIV infection in these patients with the aim of treatment would not be delayed.

Medical microbiology

10.1186/1471-2334-6-159

Cite

Citations (111)

Considerations about anesthesia in patients suffering from myopathy

G. De Francisci Montserrat Sala G Addabbo Paolo De Santis Daniel J. Galante

Dystrophies are generally classified into progressive, such as Duchenne, Becker, the Emery-Dreifuss, the Central Core, the Nemaline, the King Denborough and congenital and mitochondrial myopathies, which can be present at birth. General anesthesia in myopathic poses several problems. The patient may be a child with initial symptoms, which must be subjected to muscle biopsy or a patient with overt myopathy, with all the events muscular, respiratory and cardiac related to it, to be submitted to any operation under general anesthesia even if regional blocks are also possible. For this reason,

Nemaline myopathy

Central core disease

Congenital myopathy

Source

Cite

Citations (2)

Use of generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection in Spain

AIDS Research and Human Retroviruses (2022)

Marta Ruiz‐Algueró Belén Alejos Cristina García Yubero Melchor Riera Jaume José Antonio Iribarren

The present study sought to describe the use of generic drugs and single-tablet regimen (STR) de-simplification for the treatment of human immunodeficiency virus (HIV) infection among 41 hospitals from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). In June 2018, we collected information on when generic antiretroviral drugs (ARVs) were introduced in the different hospitals, how the decisions to use them were made, and how the information was provided to the patients. Most of the nine available generic ARVs in Spain by June 2018 had been introduced in at least 85% of the participating hospitals, except for zidovudine (AZT)/lamivudine (3TC) and AZT. The time difference between the effective marketing date of each generic ARV and its first dispensing date in the hospitals was much shorter for the more recently approved generic ARV since the year 2017. However, only up to 20% of the hospitals de-simplified efavirenz (EFV)/tenofovir disoproxil (TDF)/emtricitabine (FTC), dolutegravir (DTG)/abacavir (ABC)/3TC, and rilpivirine (RPV)/TDF/FTC (to generic EFV+TDF/FTC, DTG+generic ABC/3TC, and RPV+generic TDF/FTC, respectively), whereas the generic STR EFV/TDF/FTC was introduced in 87.8% of the centers. The median times between the date of effective marketing of generic TDF/FTC and the date of de-simplification of EFV/TDF/FTC and RPV/TDF/FTC were 723 [interquartile range (IQR): 369-1,119] and 234 (IQR: 142-264) days, respectively; this time was 155 (IQR: 28-287) days for de-simplification of DTG/ABC/3TC. In conclusion, despite the widespread use of generic ARVs, STRs de-simplification was only undertaken in <20% of the hospitals. There was wide variability in the timing of the introduction of each generic ARV after they were available in the market.

Rilpivirine

Efavirenz

Dolutegravir

Abacavir

Emtricitabine

Regimen

Interquartile range

Antiretroviral drug

Antiretroviral treatment

10.1089/aid.2021.0122

Cite

Citations (4)